Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Trea (Q33408588)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Trea |
scientific article |
Statements
1 reference
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Trea (English)
1 reference
Mary E R O'Brien
1 reference
Rabab M Gaafar
1 reference
Allan Price
1 reference
Denis C Talbot
1 reference
Tanja Cufer
1 reference
Sarah Danson
1 reference
Athanasios Pallis
1 reference
Baktiar Hasan
1 reference
Jan P Van Meerbeeck
1 reference
Paul Baas
1 reference
20 June 2013
1 reference
1 reference
49
1 reference
13
1 reference
2815-2822
1 reference
Identifiers
1 reference
1 reference